160968-99-0

Basic information

• Product Name: 2-(2,2,2-Trifluoroethoxy)phenol
• Synonyms: 2-(2,2,2-Trifluoroethoxy)phenol;2,2,2-Trifluoro-2'-hydroxyphenetole
• CAS NO: 160968-99-0
• Molecular Formula: C₈H₇F₃O₂
• Molecular Weight: 192.14
• EINECS: 1308068-626-2
• Mol File: 160968-99-0.mol

Chemical Properties

• Melting Point: 49-50 ºC
• Boiling Point: 202 ºC
• Flash Point: 102 ºC
• Appearance: colorless to pink solid
• Density: 1.327
• Vapor Pressure: 0.205mmHg at 25°C
• Refractive Index: 1.463
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
• PKA: 9.22±0.30(Predicted)
• CAS DataBase Reference: 2-(2,2,2-Trifluoroethoxy)phenol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2,2,2-Trifluoroethoxy)phenol(160968-99-0)
• EPA Substance Registry System: 2-(2,2,2-Trifluoroethoxy)phenol(160968-99-0)

Safety Data

• Hazardous Substances Data: 160968-99-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-(2,2,2-Trifluoroethoxy)phenol is used as a reactant for the preparation of phenyl acetate compounds, which are known for their short sedative and hypnotic effects. These compounds can be utilized in the development of medications aimed at treating conditions such as insomnia, anxiety, and other sleep-related disorders. The trifluoroethoxy group in 2-(2,2,2-Trifluoroethoxy)phenol may contribute to the enhanced efficacy and selectivity of the resulting phenyl acetate compounds, making them more suitable for therapeutic use.

InChI:InChI=1/C8H7F3O2/c9-8(10,11)5-13-7-4-2-1-3-6(7)12/h1-4,12H,5H2

Upstream product

• 75-89-8 2,2,2-trifluoroethanol 
• 65109-75-3 N-(phenoxy)-4-methylbenzenesulfonamide 
• 106854-74-4 2-methoxy-1-(2,2,2-trifluoroethoxy)benzene 
• 90-05-1 2-methoxy-phenol 
• 353-83-3 1,1,1-trifluoro-2-iodoethane 
• 120-80-9 benzene-1,2-diol 
• 433-06-7 2,2,2-Trifluoroethyl p-toluenesulfonate 

Downstream Products

• 160969-01-7 ethyl 2-(2,2,2-trifluoroethoxy)phenoxyacetate 
• 160969-03-9 1-(2-methanesulfonyloxyethoxy)-2-(2,2,2-trifluoroethoxy)benzene 
• 160969-00-6 1-(2-bromoethoxy)-2-(2,2,2-trifluoroethoxy)benzene 
• 160969-02-8 2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethanol 
• 1269801-74-2 2-[2-(2,2,2-trifluoroethoxy)phenoxy-ethyl]-[1,3]dioxalane 
• 160970-54-7 silodosin 
• 885340-11-4 2,3-dihydro-1-[3-(benzoyloxy)propyl]-5-[(2R)-2-[[2-[(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-1H-indole-7-carbonitrile 
• 885340-13-6 1-(3-hydroxypropyl)-5-[(2R)-2-({2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino)propyl]-2,3-dihydro-1H-indole-7-carbonitrile 
• 1269801-73-1 [2-(2,2,2-trifluoroethoxy)phenoxy]acetaldehyde 
• 1426173-86-5 C₂₅H₂₈⁽²⁾H₄F₃N₃O₄ 

Relevant articles and documents

Synthesis and pharmacological evaluation of novel silodosin-based arylsulfonamide derivatives as α1A/α1D-adrenergic receptor antagonist with potential uroselective profile

Benign prostatic hyperplasia (BPH) is the most common male clinical problem impacting the quality of life of older men. Clinical studies have indicated that the inhibition of α1A-/α1D adrenoceptors might offer effective therapy in lower urinary tract symptoms. Herein, a limited series of arylsulfonamide derivatives of (aryloxy)ethyl alicyclic amines was designed, synthesized, and biologically evaluated as potent α1-adrenoceptor antagonists with uroselective profile. Among them, compound 9 (3-chloro-2-fluoro-N-([1-(2-(2-(2,2,2-trifluoroethoxy)phenoxy]ethyl)piperidin-4-yl) methyl) benzenesulfonamide) behaved as an α1A-/α1D-adrenoceptor antagonist (Ki(α1) = 50 nM, EC50(α1A) = 0.8 nM, EC50(α1D) = 1.1 nM), displayed selectivity over α2-adrenoceptors (Ki(α2) = 858 nM), and a 5-fold functional preference over the α1B subtype. Compound 9 showed adequate metabolic stability in rat-liver microsome assay similar to the reference drug tamsulosin (Clint = 67 and 41 μL/min/mg, respectively). Compound 9 did not decrease systolic and diastolic blood pressure in normotensive anesthetized rats in the dose of 2 mg/kg, i.v. These data support development of uroselective agents in the group of arylsulfonamides of alicyclic amines with potential efficacy in the treatment of lower urinary tract symptoms associated to benign prostatic hyperplasia.

PROCESS FOR THE PREPARATION OF INDOLINE DERIVATIVES AND THEIR INTERMEDIATES THEREOF

Processes for the preparation of Silodosin and its intermediates comprising reductive amination of compound of Formula (VIII) with a compound of Formula (VII) or a compound of Formula (XV) in a suitable solvent using a reducing agent.

NOVEL PROCESS FOR THE SYNTHESIS OF PHENOXYETHYL DERIVATIVES

The present invention provides an improved process for the synthesis of 2-[2- (2,2,2-trifluoroethoxy)phenoxy]ethanol intermediate, its derivatives and/or its pharmaceutically acceptable salts, useful in the synthesis of α-1 adrenoceptor blockers such as silodosin.

PROCESS FOR THE PREPARATION OF INDOLINE DERIVATIVES AND THEIR INTERMEDIATES THEREOF

Processes for the preparation of Silodosin and its intermediates comprising reductive amination of compound of Formula (VIII) with a compound of Formula (VII) or a compound of Formula (XV) in a suitable solvent using a reducing agent.

1,5,7-trisubstituted indoline compounds and salts thereof

Indoline compounds represented by the formula: STR1 wherein R represents a saturated or unsaturated aliphatic acyl group which may have one or more halogen atoms, a hydroxy group, a lower alkoxy group, a carboxy group, a lower alkoxycarbonyl group, a cycloalkyl group or an aryl group as substituents; a hydroxyalkyl group; an aliphatic acyloxyalkyl group; a lower alkyl group having a lower alkoxy group, a carboxy group, a lower alkoxycarbonyl group, an aryl substituted lower alkoxycarbonyl group, a carbamoyl group, a mono- or dialkyl substituted carbamoyl group or a cyano group as substituents; an aromatic acyl group which may have one or more halogen atoms as substituents; a furoyl group or a pyridylcarbonyl group; R1 represents a lower alkyl group which may have one or more halogen atoms or an aryl group as substituents; and pharmaceutically acceptable salts thereof, exhibit a selective suppressive action on urethral contractions, and thus are useful as therapeutic agents for the treatment of dysuria with less hypotension including postural hypotension.

Acid-Catalyzed Solvolysis of N-Sulfonyl- and N-Acyl-O-arylhydroxylamines. Phenoxenium Ions

The acid-catalyzed reaction of N-acyl- and N-sulfonyl-O-arylhydroxylamines with benzene proceeded quite smoothly to give 2- and 4-hydroxybiphenyls.The results of product analysis, the orientation of the reaction, and the effects of substituents on the nitrogen atom and on the phenyl ring suggested a mechanism that involves a phenoxenium ion.The phenoxenium ion was trapped by benzene and other various nucleophiles.